Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Focal adhesion kinase (FAK) is crucial for cancer cell migration, proliferation, and survival.
• FAK regulates integrin and growth factor signaling pathways, making it a key target in cancer therapy.
• Existing FAK inhibitors demonstrate effectiveness in preclinical and clinical studies against tumor growth and metastasis.

Purpose of the Study:

• To review the antitumor mechanisms of dual inhibitors targeting FAK and other factors.
• To summarize the current research status of these dual-target FAK inhibitors.
• To provide insights for developing novel FAK dual-target preparations.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of signaling pathways involving FAK, Src, AKT, MAPK, PI3K, and EGFR/HER-2.
• Examination of dual inhibitors targeting FAK in combination with Pyk2, IGF-IR, ALK, VEGFR-3, JAK2, EGFR, S6K1, and HDAC2.

Main Results:

• Dual inhibitors can enhance efficacy compared to single-target inhibitors.
• Simultaneous inhibition of FAK and other targets can overcome drug resistance mechanisms.
• Various dual-target FAK inhibitors are under investigation for their antitumor potential.

Conclusions:

• Dual-target FAK inhibitors represent a promising strategy for improved cancer therapy.
• Further research into FAK dual-target preparations may lead to more effective cancer treatments.
• Understanding these mechanisms is vital for overcoming limitations of current single-target therapies.